CERV-215 Cells

The CERV-215 cell line, established by Dr. Bodgen at the Mason Research Institute, originates from a primary xenotransplant termed MRI-H215, which has been adapted for in vivo transplantation.
This cell line represents an aggressive form of epidermoid carcinoma, categorized as invasive, large cell, non-keratinizing, and poorly differentiated.
The Cerv-215 cell line, is a pivotal resource for cancer research, especially in the study of genetic alterations and their roles in cervical carcinogenesis. This cell line is characterized by unique genetic modifications in the Smad4 gene, where specific exons are replaced by sequences from other genomic regions, leading to the expression of truncated and likely non-functional Smad4 proteins. These alterations provide insights into the cell line's oncogenic properties and the molecular mechanisms underlying cervical cancer.
Notably, MRI-215 is HPV45 positive, yet its Smad4 gene alterations are independent of HPV integration, suggesting a complex interplay of genetic factors contributing to cancer development beyond viral influences. This cell line serves as an invaluable tool for researchers focusing on the genetic aspects of cancer, the role of Smad4 in tumor progression, and the interaction between human papillomavirus and host cellular mechanisms.
MRI-H215 offers a unique platform for exploring the intricacies of cervical cancer at the molecular level, making it an essential component of cancer research laboratories aiming to uncover new therapeutic targets and understand the genetic basis of tumorigenesis.